J. Egberts

Biography

  Mr. Egberts has over 25 years of executive experience in the pharmaceutical and medical device sectors, most recently as Chief Executive Officer at Agendia Inc., a molecular diagnostics company.  Prior to this, Mr. Egberts was Chief Executive Officer of OctoPlus N.V., a specialty pharmaceutical company, which was acquired by Dr. Reddy’s Laboratories Ltd. in 2013.  Mr. Egberts also served as a senior healthcare advisor for 3i Group plc, a private equity firm and as President, Chairman and Chief Executive Officer of NovaDel Pharmaceuticals Inc., where he developed a portfolio of pre-clinical and clinical compounds, gaining FDA approval for two compounds.  In addition, Mr. Egberts has held multiple business development and general management positions at Johnson & Johnson, Merck & Co. and Mölnlycke Health Care.  Mr. Egberts graduated from Erasmus University Medical School in the Netherlands and he obtained his MBA from Stanford after which he worked as a management consultant for McKinsey & Co. Mr. Egberts continues to serve on the supervisory board of CHDR (Center for Human Drug Research) and Implanet SA.

Research Interest

      pharmaceutical sciences